SCHEMBL4661391

SCHEMBL4661391

Cc1cc(=O)n(-c2ccc(NS(=O)(=O)c3ccccc3)cn2)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.45
GAA P10253 2/20 0.45
NR1I2 O75469 1/20 0.43
BRD4 O60885 3/20 0.43
BRD1 O95696 1/20 0.43
BRPF1 P55201 1/20 0.43
BRD9 Q9H8M2 1/20 0.43
BRPF3 Q9ULD4 1/20 0.43
TRIM24 O15164 1/20 0.43
NPY5R Q15761 1/20 0.42
KDM5A P29375 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
PKM P14618 1/20 0.41
CYTH2 Q99418 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13248881 0.90 KIT (0.48) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248887 0.89 KMT2A (0.56) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248894 0.89 KIT (0.47) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248893 0.88 KMT2A (0.45) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248882 0.88 PGR (0.52) ALDH1A1KMT2AMAPTBRD4PKM
SCHEMBL13248877 0.88 HSD17B2 (0.50) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248875 0.88 KIT (0.46) ALDH1A1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL13248890 0.88 KMT2A (0.50) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248872 0.87 GAA (0.57) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL13248884 0.87 KIT (0.49) ALDH1A1KMT2AMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS ASTRAZENECA AB (SE) 2010-07-15 US disclosed
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS ASTRAZENECA AB (SE) 2010-07-15 US disclosed
EP-1919890-A1 PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS AstraZeneca AB (SE) 2008-05-14 EP disclosed
WO-2007020426-A1 PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS ASTRAZENECA AB (SE) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179161-A1 PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS TREH, TYMP, EPX ALDH1A1 965/4885KMT2A 4691/4885MAPT 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.